

Getting Nanotechnology Right the First Time

Presentation to the National Research Council
Committee to Review the National Nanotechnology Initiative
25 March 2005

Richard A. Denison, Ph.D.
Senior Scientist
Health Program



ENVIRONMENTAL DEFENSE

finding the ways that work


Introduction to Environmental Defense

- Founded in 1967
- 250 scientists, economists, attorneys and other professionals in 8 offices
 - *Most PhDs of any environmental advocacy organization*
- Funded by foundations, benefactors and 400,000 members
- Longstanding involvement, expertise in partnership approaches to promote environmental technologies and manage chemical risks
 - *Catalyzed launch of US High Production Volume (HPV) Chemical Challenge program*



At the nano-scale, materials act differently



Tiny changes make big differences



Novel Properties Will Bring Breakthroughs



...But May Also Bring Unexpected Risks: Preliminary studies raise concerns

Mobility

- **Through groundwater?**
- **Bioaccumulation?**
- **Across blood-brain barrier?**
- **Across placenta?**




Toxicity

- **Aquatic toxicity?**
- **Cytotoxicity?**
- **Lung granulomas and fibrosis?**
- **Brain lipid peroxidation?**

...Even to Everyday Products Available Now



Why does this sound familiar?



Questions about nanotoxicity

- What is the fate of nanomaterials over their full lifecycle (production, use, disposal/release)?
- Will nanoparticles build up over time?
- How will living organisms/systems respond if exposures occur?
- How mobile and persistent are these materials in the environment and organisms?
- Are their transformation (e.g., degradation) products more or less toxic?

Getting it right the first time


- Possibly transformative technology
- Potential significant downside
- Still at early stage of development

Four Keys to Responsible Nanotechnology Development

- **Increase government risk research**
- **Develop clear government regulatory policies**
- **Implement proactive risk management standards**
- **Engage stakeholders in setting agenda**

Increase Funding for Risk Studies

Annual U.S. Spending on Nanotech R&D



Total = \$3.5B

Is Our Current Regulatory System Up to the Task?

Breadth of applications

- *Consumer products*
- *Personal care/cosmetics*
- *Medical applications*
- *Coatings*
- *Electronics*
- *Catalysts*


Multitude of federal agencies

- *Occupational Safety and Health Administration (OSHA)*
- *Environmental Protection Agency (EPA)*
- *Food and Drug Administration (FDA)*
- *Consumer Product Safety Commission (CPSC)*

EPA: TSCA Complexities / Limitations

- When are nanomaterials “new” chemicals?
- Existing exemptions (e.g., weight threshold)
- No up-front data requirements for new chemicals
- Significant burden on EPA to require testing
- Poor basis for evaluating risk in absence of data on specific types of nanomaterials
- Nomenclature confusion

Close Regulatory “Nano-Loopholes”



- Many gaps in current regulations create uncertainty
 - *Uncertainty about applicability*
 - *Few requirements for pre-market testing*
 - *Authority to respond to problems largely after-the-fact*
- Clear, protective regulations needed to set level playing field
 - *Clarify, enhance authorities as needed*
 - *Adequate scrutiny before marketing*
 - *Apply use restrictions where necessary*

Proactive Risk Identification & Management

- Acknowledge that nanomaterials are different
 - *Hazards cannot be inferred from bulk materials*
- Commit to up-front research and testing
 - *Sufficient testing to identify risks prior to commercialization*
- Take a responsible approach to managing risks
 - *Risks addressed across the lifecycle*
 - *Protective interim risk management in advance of testing*
 - *Appropriate risk management in response to testing, monitoring*
- Embrace transparency
 - *Public disclosure of all risk-related information*
 - *Labeling, accurate MSDS disclosures*

Responsible Interim Risk Management Approaches

- Interim worker safety steps
 - *Assume toxicity until shown otherwise*
 - *Worker training, industrial hygiene, PPE*
 - *Workplace, worker health monitoring*
 - *Wastes treated as hazardous materials*
- Interim environmental safety steps
 - *Restrict dispersive uses until hazard and exposure/fate data available*
 - *Manufacturers assess and disclose lifecycle risks in advance of commercialization*
 - *Release/environmental monitoring*

What should NSET be doing?

- Ensure more federal research dollars are spent on health & environmental implications of nanotechnology
 - *At least 10-fold increase, to \$100 million/yr*
- Oversee assessment of federal agency jurisdictions and regulatory authorities
 - *Identify changes needed to address gaps, uncertainties*
 - *May require enhancing function/authority of NSET*
- Actively engage stakeholders beyond industry, gov't.
 - *Beyond “top-down” public education, risk communication*
 - *Acknowledge value of perspective, relevant expertise*
 - *Involve stakeholders in setting agenda*

What can this Committee do?

- Request detailed figures on what is being spent on risk-related research across the various NNI agencies
 - *Review adequacy relative to the tasks at hand*
- Draw on expertise of the NRC Board on Env'l. Studies and Toxicology and other experts to review ongoing research and research plans
- Identify gaps in existing statutory authorities and regulatory programs
 - *Call for creation of new authorities and programs as needed*
- Facilitate active engagement of stakeholders to help inform and guide the NNI and its research agenda
 - *Incorporate interests and concerns of workers, consumers, health and environmental advocates*